Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

Ipamorelin

Growth hormoneClinical trialsPubMed records: 45count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O Ipamorelin é um pentapeptídeo sintético e secretagogo seletivo de GH que age via receptor de grelina (GHS-R1a). Seu diferencial principal é a seletividade: diferentemente de outros peptídeos da classe (GHRP-6, Hexarelin), o Ipamorelin estimula a liberação de GH sem elevar significativamente cortisol ou prolactina (PMID: 9849822). Isso o torna o secretagogo de GH mais 'limpo' do catálogo, com menor risco de efeitos colaterais hormonais indesejados. Original in PT-BR

Ipamorelin is catalogued under Growth hormone. 31 Eagle articles in this library reference this compound.

Category
Growth hormone
Research stage
Clinical trials — Fase 2 Clínica Original in PT-BR
PubMed records
45 (count from PubMed, not curated)
Eagle articles on this compound
31 Eagle articles

Mechanism

Secretagogo de GH mais seletivo via receptor de grelina — NÃO eleva cortisol nem prolactina Original in PT-BR

O Ipamorelin mimetiza a grelina no receptor GHS-R1a da pituitária, estimulando a liberação de GH pelos somatotrofos. Porém, sua seletividade molecular faz com que ative apenas a via de liberação de GH, sem desencadear a cascata de ACTH/cortisol ou a via dopaminérgica que elevaria prolactina. Em estudos humanos, doses de 1 mcg/kg produziram liberação significativa de GH sem alteração de cortisol, ACTH, prolactina ou TSH (PMID: 15265829). Isso o torna ideal para uso crônico e para pacientes sensíveis a alterações hormonais. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
170851-70-4
Molecular formula
C₃₈H₄₉N₉O₅
Molecular weight
711,85 g/mol pt-BR notation
Sequence
Aib-His-D-2Nal-D-Phe-Lys-NH2 Original in PT-BR
Amino acids
Not recorded in the source.
Solubility
Água bacteriostática Original in PT-BR
Stability
Estável reconstituído por 21 dias refrigerado (2–8 °C) Original in PT-BR
Half-life
~2 horas Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
Pico de GH em 30–60 minutos Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

65/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Estudo seminal demonstrando que Ipamorelin é o primeiro secretagogo seletivo de GH — libera GH sem elevar cortisol, ACTH, prolactina ou aldosterona. Original in PT-BR

    PMID: 9849822Year: 1998Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Em voluntários humanos saudáveis, Ipamorelin produziu liberação dose-dependente de GH com preservação do perfil hormonal (sem alteração de cortisol/prolactina). Original in PT-BR

    PMID: 15265829Year: 2004Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Leve inchaço no sítio de injeção
  • Flush facial leve (menos que CJC-1295)
  • Formigamento transitório nas extremidades

Serious

  • Perfil de segurança favorável — o mais seletivo e 'limpo' dos secretagogos
  • Superdosagem crônica pode causar efeitos de excesso de GH (retenção hídrica, artralgia)

Contraindications

  • Câncer ativo
  • Diabetes descontrolado
  • Gravidez ou amamentação

Warnings

  • Não comer 2h antes da aplicação noturna
  • Monitorar IGF-1 para ajuste de dose
  • Aplicar deitado para minimizar qualquer flush residual

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for Ipamorelin.

Lab tests named in the source

  • IGF-1
  • GH basal
  • Glicemia de jejum
  • Insulina
  • Cortisol matinal

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose Padrão
200–300 mcg SC antes de dormir Original in PT-BR
Frequência
1x ao dia (noturno) ou 5 on / 2 off Original in PT-BR
Ciclo
8–12 semanas ON / 4 semanas OFF Original in PT-BR
Timing
30–60 min antes de dormir, em jejum Original in PT-BR
UI na Seringa
10 UI = 250 mcg (frasco 5mg / 2mL BAC) Original in PT-BR

Vial sizes: 2mg · 5mg — Peptide Calculator

Interactions

This section brings together two origins. The ones Eagle wrote come from its own curated library, one by one; the rest come from the imported reference material, which records one label and one comment per pair and no source. Neither kind carries a PMID, a population or model, or a degree of certainty. Eagle did not verify the imported ones and does not endorse them. «Compatible», «Caution» and «Avoid» are not an Eagle authorisation or prohibition, and none of this is medical advice.

Reported synergy

  • CJC-1295 sem DAC

    O 'Golden Combo': Ipamorelin (via grelina) + CJC-1295 (via GHRH) = duas vias simultâneas = liberação de GH amplificada. Padrão-ouro. Original in PT-BR

Compatible

Related

View all (31)

← Back to knowledge area